Tools for Your Organization

We’ve worked with leading experts to develop a range of tools and resources to help Employers address the impact of chronic diseases like multiple sclerosis (MS) in the workplace

The MS Estimator

How many adults in your organization could have MS?

What’s the impact of MS on your organization? This tool uses a validated algorithm to estimate the number of employees in an organization that may be impacted by MS.

Get Your Estimate >

How many adults in your organization could have MS?

MS is More Common Than Everyone Realized!

Up until 2019, MS was thought to affect about 350,000 individuals in the US. However, more recent data reveals that the number of people with MS is actually nearing 1 million individuals.1

Location, age and gender have a lot to do with how many individuals could have MS.

Using a validated algorithm, we estimate the number of adults with MS in your organization and generate results based on your input.

1Wallin MT, et al. Neurology. 2019 Mar 5;92(10):e1029-e1040

Tell us a little about yourself
Choose one:

Results Ready!

We’re analyzing your data inputs now and we’ll show the results for your organization on-screen in a moment.
Please provide the following information so we can send you an email with the results of your inputs.

Please enter your first name
Please enter your last name
Submitting data...
There was an error submitting your data. Please try again or click here to proceed anyway >
No thanks, proceed anyway >
Roughly, what ratio are male/female?

Based on newly available data,
[XX-XX] of your employees may have MS1

When you add in loved ones of those not covered under your plan, including MS patients on Medicare, these numbers could increase significantly. Estimates are based on a validated algorithm used to estimate the prevalence of MS from multiple sets of administrative health data including 125 million individuals over 18 years of age. For more details click here.

See US Prevalence by Gender, Age and Geography >

< Start Over

Reference: 1. Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029-e1040. doi: 10.1212WNL0000000000007035.

Estimates are representational only and made available for informational and educational purposes only. Bristol Myers Squibb does not make any representation or warranties with respect to the accuracy, applicability, fitness, or completeness of any estimate generated.

More Tools for Your Organization

Caregiver Census

Caregiver Census

We’ve partnered with the non-profit Caregiver Action Network (CAN) to develop a survey that Employers can use to better understand the prevalence of caregiving among their employees.

How to Have a Conversation with Your Employee

How to Have a Conversation with Your Employee

We’ve storyboarded a hypothetical conversation between an employee (newly diagnosed with MS) and their Human Resources contact. See what good can sound like.

Implementing a Successful Support Program

Implementing a Successful Support Program

Learn how one large Employer reduced health plan costs while implementing a successful program to address the unique needs of employees with chronic diseases like MS.

Benefits Checklist

Benefits Checklist

As you evaluate annual benefit offerings for your organization, consider using this framework to support your assessment of health plans and PBM offerings in the area of MS.

Study Description


To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets.

Data Source

Several AHC datasets representing the US private and government-sponsored insurance programs which included Optum (OP), Truven Health (TH), Kaiser Permanente Southern California (KPSC), Centers for Medicare & Medicaid Services, Department of Defense and Veteran Affairs.


A validated algorithm was applied to each dataset, to determine the 3-year cumulative prevalence overall and stratified by age, sex, and census region for adults (≥18 years of age). Insurance-specific and stratum-specific estimates were applied to the 2010 US Census data. The findings were pooled to calculate the 2010 prevalence of MS in the United States cumulated over 3 years. The study estimated the 2010 prevalence cumulated over 10 years using 2 models and extrapolated the estimate to 2017.

Study Outcomes

Estimated 2010 US MS prevalence accumulated over 10 years. Also, extrapolated date to 2017 prevalence.


Results may not be generalizable to the entire US population. This study assessed 100% of publicly funded population but not the uninsured population or children 18 years of age within the US.


  • The study did not include children, the Indian Health Service, the US prison system, or undocumented US residents in our prevalence estimates.
  • Those with MS not followed in the traditional health care system (e.g., alternative medicine or cash health care practices that bypass health insurance reimbursement) would be missed by our method. This would result in an underestimate of MS cases.
  • Study did not characterize the racial or ethnic demographics of our MS population in this report because race and ethnicity were not uniformly collected in the AHC datasets used.
  • The majority of datasets, except VA, contained less than 10 years of data.

Stay Informed

  • Be the first to be informed about new content and resources

  • By clicking the Submit button, I authorize Bristol Myers Squibb, its affiliates, and its agents to analyze and use my information to improve or develop services and programs and to contact me about market research and other information that it believes may be of interest to me. This could include education about chronic diseases and the workplace and information about treatment options made by Bristol Myers Squibb. Bristol Myers Squibb will not sell or rent your personal information. From time to time the Privacy Policy may change and you should check the website at for the most recent version. Please click “unsubscribe” on e⁠mail communications to opt out of e-mails.
  • This field is for validation purposes and should be left unchanged.
You are now leaving and going to a third party website.

The content of the linked site is the sole responsibility of the site provider. Bristol Myers Squibb does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to

< CancelOK >